These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37968543)

  • 1. Cascade testing in Italian Hereditary Breast Ovarian Cancer families: a missed opportunity for cancer prevention?
    Trevisan L; Godino L; Battistuzzi L; Innella G; Luppi E; Buzzatti G; Gismondi V; Blondeaux E; Bonelli LA; Turchetti D; Varesco L
    Fam Cancer; 2024 Jun; 23(2):197-207. PubMed ID: 37968543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facilitated cascade testing (FaCT): a randomized controlled trial.
    Nitecki R; Moss HA; Watson CH; Urbauer DL; Melamed A; Lu KH; Lipkin SM; Offit K; Rauh-Hain JA; Frey MK
    Int J Gynecol Cancer; 2021 May; 31(5):779-783. PubMed ID: 33443030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
    Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS
    Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
    Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted sequencing for hereditary breast and ovarian cancer in BRCA1/2-negative families reveals complex genetic architecture and phenocopies.
    Plowman JN; Matoy EJ; Uppala LV; Draves SB; Watson CJ; Sefranek BA; Stacey ML; Anderson SP; Belshan MA; Blue EE; Huff CD; Fu Y; Stessman HAF
    HGG Adv; 2024 Jul; 5(3):100306. PubMed ID: 38734904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis.
    Ahsan MD; Chandler IR; Min S; Grant B; Primiano M; Greenwald J; Soussana TN; Baltich Nelson B; Thomas C; Chapman-Davis E; Sharaf RN; Frey MK
    Clin Obstet Gynecol; 2024 Dec; 67(4):702-710. PubMed ID: 39431491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized Trial.
    Grisham C; Peshkin BN; Sorgen L; Isaacs C; Ladd MK; Jacobs A; Binion S; Tynan M; Kuchinsky E; Friedman S; Taylor KL; Graves K; O'Neill S; Kim D; Schwartz MD
    Public Health Genomics; 2024; 27(1):100-109. PubMed ID: 39173603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cascade screening in HBOC and Lynch syndrome: guidelines and procedures in a UK centre.
    Evans DG; Green K; Burghel GJ; Forde C; Lalloo F; Schlecht H; Woodward ER
    Fam Cancer; 2024 Jun; 23(2):187-195. PubMed ID: 38478259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-gene panel analysis in BRCA1/2-negative patients suspected of hereditary breast and ovarian cancer syndrome: Real-world data from a single institution.
    Nakahara M; Ushiama M; Tanabe N; Gotoh M; Sakamoto H; Yoshida T; Hirata M
    J Obstet Gynaecol Res; 2024 Sep; 50(9):1591-1597. PubMed ID: 39077936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
    JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands.
    Yoshida R; Kaneyasu T; Ueki A; Yamauchi H; Ohsumi S; Ohno S; Aoki D; Baba S; Kawano J; Matsumoto N; Nagasaki M; Ueno T; Inari H; Kobayashi Y; Takei J; Gotoh O; Nishi M; Okamura M; Kaneko K; Okawa M; Suzuki M; Amino S; Inuzuka M; Noda T; Mori S; Nakamura S
    Breast Cancer; 2024 Nov; 31(6):1028-1036. PubMed ID: 39003386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review.
    Afaya A; Kim SW; Park HS; Lim MC; Jung MS; Nam EJ; Park JS; Jeong J; Ryu JM; Kim J; Kim J; Kim M; Jin J; Han J; Kim SY; Park SY; Katapodi MC; Kim S;
    Fam Cancer; 2024 Jun; 23(2):121-132. PubMed ID: 38662264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse Asian setting.
    Lee DS; Meiser B; Mariapun S; Hassan T; Yip CH; Mohd Taib NA; Teo SH; Thong MK; Yoon SY
    J Genet Couns; 2021 Jun; 30(3):720-729. PubMed ID: 33245177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline Genetic Testing for Hereditary Breast and Ovarian Cancer: Current Concepts in Risk Evaluation.
    Yadav S; Couch FJ; Domchek SM
    Cold Spring Harb Perspect Med; 2024 Aug; 14(8):. PubMed ID: 38151326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
    Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
    Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.